Arrowstreet Capital’s Sarepta Therapeutics SRPT Stock Holding History

Arrowstreet Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,636	Closed	-$572K	–	1445
2022 Q2	$572K	Buy	+7,636	New	+$562K	﹤0.01%	1049
2021 Q1	–	Sell	-19,100	Closed	-$3.26M	–	2514
2020 Q4	$3.26M	Buy	+19,100	New	+$2.83M	﹤0.01%	1405
2018 Q1	–	Sell	-3,900	Closed	-$217K	–	1324
2017 Q4	$217K	Buy	+3,900	New	+$207K	﹤0.01%	1174
2013 Q4	–	Sell	-16,343	Closed	-$772K	–	1280
2013 Q3	$772K	Buy	+16,343	New	+$629K	﹤0.01%	718

Other funds holding SRPT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Arrowstreet Capital's SRPT Position: Q3 2022 in Review

Arrowstreet Capital sold out of Sarepta Therapeutics (SRPT) in Q3 2022, closing a stake of 7,636 shares — an estimated $572K sold.

Arrowstreet Capital first reported a position in SRPT in Q3 2013 and held it in 4 quarters. The position peaked at $3.26M in Q4 2020. 375 funds tracked by Wall St. Rank hold SRPT as of Q3 2022.

Arrowstreet Capital reported no remaining Sarepta Therapeutics position as of Q3 2022 after selling out during the quarter.
Arrowstreet Capital sold 7,636 Sarepta Therapeutics shares in Q3 2022, an estimated $572K.
Arrowstreet Capital first reported a position in Sarepta Therapeutics in Q3 2013 and held it in 4 quarters.
Arrowstreet Capital's Sarepta Therapeutics position peaked at $3.26M in Q4 2020.
375 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2022.

Based on Arrowstreet Capital's 13F filing for Q3 2022, filed 14 Nov 2022.